drug
(cytarabine hydrochloride + daunorubicin hydrochloride)
Marketedupdated 5mo agoby $JAZZ Jazz Pharmaceuticals plc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(0)
nothing on the calendar yet
Trials studying (cytarabine hydrochloride + daunorubicin hydrochloride)
- phase1CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
- phase1Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
- —VYxeoS Liposomal Italian Observational Study iN the Real Practice
- phase1Vyxeos® With Clofarabine for Pediatric AML
- N/AA Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 23, 2027
111 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Apr 15, 2033patentUS 10028912*PED
- Apr 15, 2033patentUS 10166184*PED
- Apr 15, 2033patentUS 10835492*PED
- Oct 15, 2032formulationUS 10028912
- Oct 15, 2032formulationUS 10166184
- Oct 15, 2032method-of-use (U-3150)US 10835492
- Oct 1, 2029patentUS 8092828*PED3.0y
- Apr 1, 2029method-of-use (U-3147)US 80928282.5y
- Mar 14, 2028patentUS 8022279*PED1.4y
- Sep 14, 2027formulationUS 8022279345d
- Jul 23, 2027patentUS 7850990*PED292d
- Jul 23, 2027patentUS 9271931*PED292d
- Jan 23, 2027formulationUS 7850990111d
- Jan 23, 2027formulationUS 9271931111d
- Jun 7, 2026formulationUS 8518437
FDA exclusivities (2)
- Sep 30, 2028PEDPediatric (6mo bonus)2.0y
- Mar 30, 2028ODE-350Orphan Drug (7y)1.5y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that